Hengrui Pharmaceuticals

Explore the latest insights on Hengrui Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Hengrui Pharmaceuticals and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis
CompanyDrug

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Ascletis Pharma Inc. (HKG: 1672) announced positive results from a randomized, double‑blind, placebo‑controlled 28‑day proof‑of‑concept clinical trial of ASC50 in U.S. patients with mild‑to‑moderate plaque psoriasis. ASC50 is an in‑house…

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Novo Nordisk Licenses Hengrui's HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Novo Nordisk Licenses Hengrui’s HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Jiangsu Hengrui’s CD79b Targeting ADC SHR-A1912 Earns FDA Fast-Track Designation for R/R DLBCL

CompanyDrug

Jiangsu Hengrui Receives NMPA Approval for Phase II Study of GLP-1 Agonist for Weight Loss

Company

Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain

CompanyDrug

Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL

CompanyDeals

China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews

CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study

CompanyDrug

Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Nod for SGLT-2 Inhibitor and Metformin Combo for Type 2 Diabetes

Show More